PMC:7228307 / 1434-1685 JSONTXT

{"project":"LitCovid-PubTator","denotations":[{"id":"25","span":{"begin":159,"end":165},"obj":"Chemical"}],"attributes":[{"id":"A25","pred":"tao:has_database_id","subj":"25","obj":"MESH:D011134"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"hips between FcγRs and antibodies is fueling efforts to develop more potent “next‐gen” therapeutic antibodies. Such development strategies now include focused glycan or protein engineering of the Fc to increase affinity and/or tailor specificity for s"}

{"project":"LitCovid-PD-FMA-UBERON","denotations":[{"id":"T8","span":{"begin":169,"end":176},"obj":"Body_part"}],"attributes":[{"id":"A8","pred":"fma_id","subj":"T8","obj":"http://purl.org/sig/ont/fma/fma67257"}],"text":"hips between FcγRs and antibodies is fueling efforts to develop more potent “next‐gen” therapeutic antibodies. Such development strategies now include focused glycan or protein engineering of the Fc to increase affinity and/or tailor specificity for s"}

{"project":"LitCovid-PD-CLO","denotations":[{"id":"T16","span":{"begin":13,"end":15},"obj":"http://purl.obolibrary.org/obo/CLO_0052676"},{"id":"T17","span":{"begin":16,"end":18},"obj":"http://purl.obolibrary.org/obo/CLO_0008882"},{"id":"T18","span":{"begin":151,"end":158},"obj":"http://purl.obolibrary.org/obo/CLO_0009985"},{"id":"T19","span":{"begin":196,"end":198},"obj":"http://purl.obolibrary.org/obo/CLO_0052676"}],"text":"hips between FcγRs and antibodies is fueling efforts to develop more potent “next‐gen” therapeutic antibodies. Such development strategies now include focused glycan or protein engineering of the Fc to increase affinity and/or tailor specificity for s"}

{"project":"LitCovid-PD-CHEBI","denotations":[{"id":"T6","span":{"begin":169,"end":176},"obj":"Chemical"}],"attributes":[{"id":"A6","pred":"chebi_id","subj":"T6","obj":"http://purl.obolibrary.org/obo/CHEBI_36080"}],"text":"hips between FcγRs and antibodies is fueling efforts to develop more potent “next‐gen” therapeutic antibodies. Such development strategies now include focused glycan or protein engineering of the Fc to increase affinity and/or tailor specificity for s"}

{"project":"LitCovid-sample-CHEBI","denotations":[{"id":"T2","span":{"begin":169,"end":176},"obj":"Chemical"}],"attributes":[{"id":"A2","pred":"chebi_id","subj":"T2","obj":"http://purl.obolibrary.org/obo/CHEBI_36080"}],"text":"hips between FcγRs and antibodies is fueling efforts to develop more potent “next‐gen” therapeutic antibodies. Such development strategies now include focused glycan or protein engineering of the Fc to increase affinity and/or tailor specificity for s"}

{"project":"LitCovid-sample-Pubtator","denotations":[{"id":"25","span":{"begin":159,"end":165},"obj":"Chemical"}],"attributes":[{"id":"A25","pred":"pubann:denotes","subj":"25","obj":"MESH:D011134"}],"text":"hips between FcγRs and antibodies is fueling efforts to develop more potent “next‐gen” therapeutic antibodies. Such development strategies now include focused glycan or protein engineering of the Fc to increase affinity and/or tailor specificity for s"}

{"project":"LitCovid-sample-PD-FMA","denotations":[{"id":"T8","span":{"begin":169,"end":176},"obj":"Body_part"}],"attributes":[{"id":"A8","pred":"fma_id","subj":"T8","obj":"http://purl.org/sig/ont/fma/fma67257"}],"text":"hips between FcγRs and antibodies is fueling efforts to develop more potent “next‐gen” therapeutic antibodies. Such development strategies now include focused glycan or protein engineering of the Fc to increase affinity and/or tailor specificity for s"}